New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity

Zealand Pharma announced Phase 2 ZUPREME-1 trial results showing petrelintide, an amylin analog, achieved clinically meaningful double-digit weight loss (up to 10.7% vs 1.7% placebo) with placebo-like tolerability and low GI adverse event discontinuation rates (1.5%). The treatment also improved cardiometabolic risk factors. Phase 3 trials are planned for the second half of 2026.